JP2011016792A - Uric acid level lowering composition - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a uric acid level lowering composition having excellent hypouricemic action, easily and safely takable for a long time without causing side effects and contributing to prevention and amelioration of hyperuricemia.SOLUTION: The uric acid level lowering composition contains an active component comprising an acid-treated residue obtained by hydrolyzing a plant of genus Panax, family Araliaceae in the presence of an aqueous solution of a strong acid and a lower alcohol, adding water to the hydrolyzate and filtering the product. The plant of genus Panax, family Araliaceae is preferably Panax Noto ginseng.

Description

  The present invention relates to a composition for lowering uric acid level, which is derived from a plant belonging to the genus Arionaceae and has an excellent uric acid level lowering action.

  Uric acid is produced in the liver from a purine body taken from food in an almost constant amount, and almost the same amount as the produced amount is mainly filtered out from the kidney into the urine and excreted. However, if the balance between uric acid production and excretion is lost due to some cause (for example, eating habits, alcohol consumption, stress, decreased kidney function, effects of drugs, genetic factors, etc.), the amount of uric acid in the body increases too much. May cause uricemia. When the uric acid level in the body increases and the blood uric acid level exceeds 7.0 mg / dL, hyperuricemia is determined. When hyperuricemia is left for a long period of time, excessive urate causes the formation of urate crystals in the vicinity of joints and cartilage tissues and induces gout arthritis.

There are an estimated 5 million hyperuricemia patients who are gout reserves in Japan, and the number of hyperuricemia patients has become younger, and the number of patients has more than doubled over the past 20 years. Yes.
Currently, there are drugs for the treatment of hyperuricemia, but if you stop taking it, it will return to the state of hyperuricemia again. On the other hand, side effects such as fever, rash, liver damage and abnormal renal function have been observed. Therefore, a therapeutic agent for hyperuricemia is strongly desired that can be safely and comfortably taken for a long time and has no side effects.

Under such circumstances, various plant-derived uric acid level lowering compositions and the like without side effects have been studied.
For example, a uric acid level inhibitor that uses activated carbon made from coconut shell as an active ingredient has been proposed (see Patent Document 1).
Moreover, the uric acid value reducing agent which uses a ginkgo biloba extract as an active ingredient, and the food-drinks containing this are proposed (refer patent document 2).
Moreover, the uric acid value lowering agent which contains the tea polyphenol derived from tea as an active ingredient is proposed (refer patent document 3).
In addition, a xanthine oxidase inhibitor, a blood uric acid level-lowering agent, a hyperuricemia preventing or improving agent, a gout preventing agent, and a food and drink containing these agents, comprising a pomegranate extract as an active ingredient Products, pharmaceuticals, and cosmetics have been proposed (see Patent Document 4).
In addition, for the purpose of promoting the excretion of toxins in the body, such as harmful substances and waste products (uric acid, etc.) generated by metabolic activities of the living body, a composition for purifying the body containing herbal medicines such as carrots and ginseng Foods, bathing agents, cosmetics, preparations and harmful metal excretion promoters used have been proposed (see Patent Document 5).
In addition, a willow mixture is proposed in which one of Densiti (Sanshichi), Panax ginseng, etc. is mixed with a willow plant material in the form of a powder of the willow plant, which promotes increased discharge of uric acid, etc. (patent) Reference 6).
In addition, a sauna using medicinal herbs such as ginseng has been proposed for the purpose of imparting efficacy to symptoms such as gout (see Patent Document 7).
In addition, it has been reported that ginseng is administered to hyperlipidemic patients for a long period of time and effects on the body such as blood uric acid level (see Non-Patent Document 1).

  However, at present, there are no uric acid level-reducing compositions that can be safely and comfortably taken for a long period of time instead of the drugs used as therapeutic drugs for hyperuricemia. It is.

JP 2005-187405 A JP 2002-370980 A Japanese Patent Laid-Open No. 2002-212085 JP 2006-16340 A JP 2007-153888 A JP-A-9-208479 JP-A-3-9752

Proc. Symp. WAKAN-YAKU 16, p. 188 (1983)

  An object of the present invention is to solve the conventional problems and achieve the following objects. That is, the present invention provides an uric acid level-lowering composition that has an excellent uric acid level-lowering action, can be safely and comfortably taken without any side effects, and contributes to prevention and improvement of hyperuricemia. With the goal.

Means for solving the problems are as follows. That is,
<1> A uric acid level-decreasing composition characterized by containing, as an active ingredient, an acid-treated product residue obtained by hydrolyzing a urchinaceae Tochibanin genus plant in the presence of a strong acid aqueous solution and a lower alcohol, followed by hydrofiltration. is there.
<2> The uric acid level-decreasing composition according to <1>, wherein the genus Araceae is a ginseng.
<3> The uric acid value according to any one of <1> to <2>, which is used for a blood uric acid level-lowering agent, a hyperuricemia preventing agent, a hyperuricemia improving agent, a gout preventing agent, and a gout improving agent A lowering composition.

  According to the present invention, the conventional problems can be solved and the object can be achieved, the present invention has an excellent uric acid level lowering action, can be safely and comfortably taken for a long time without side effects, Furthermore, a uric acid level-reducing composition that contributes to prevention and improvement of hyperuricemia can be provided.

(Uric acid level lowering composition)
The uric acid level-reducing composition of the present invention comprises an acid-treated product residue obtained by hydrolyzing an Argyceae plant as belonging to the presence of a strong acid aqueous solution and a lower alcohol as an active ingredient. Depending on the case, other components are included.

<Resistance of acid-treated product of Arsiaceae plant>
The plant belonging to the genus Tocobanin is not particularly limited and may be appropriately selected depending on the intended purpose. , Aka: ginseng (carrot carrot), ginseng (carrot carrot)), tochiban carrot (aka: ginseng carrot), american carrot (aka: western ginseng, western ginseng)), Vietnamese carrots, Himalayan carrots, Ginseng-like carrots, Carrionaceae carrots, Nanaha carrots (Anthony carrots, also known as Chikukonshichi), Sansou Haba (Uyosanshichi), Shuryo Ginseng (Shureikainjin, also known as: Chikutsu Sansichi), Ohba 7 (Daiyo Sanshichi), Ehime Sanchichi (Gabisanshichi), Gyosan Sanchichininjin (aka: Tsukusanshichi), honeybee carrot, Nosanshichininjin (aka: Sanjou Shichichi) (etc.) Can be mentioned. Among these, the ginseng and the ginseng are preferred, and the ginseng is more preferred from the viewpoint of being stably available.

  As the plant belonging to the genus Totibandin, it may be used as it is collected from nature, but since the roots and rhizomes contain a particularly large amount of active ingredients, the roots and rhizome parts, and this were crushed It is preferable to use a powder. Among these, a powdery one is preferable from the viewpoint of efficiently performing the acid treatment described later.

The acid-treated product residue of the genus Tochibanin ginseng plant exhibits a superior uric acid level lowering effect than the use of the Uchigaceae Tochibanin ginseng plant.
The reason for this is that when the above-mentioned Araceae Tochibanin genus plant is acid-treated, the sugar is released from the glycoside (saponin), which is a medicinal component contained in the plant body, and panaxatriol (PT), panaxadiol (PD), proto Sapogenins (aglycone bodies) such as panaxatriol (PPT) and protopanaxadiol (PPD) are produced. These sapogenins are considered to exhibit the uric acid level lowering action as an active ingredient.
There is no restriction | limiting in particular as content rate of the said sapogenin in the said acid-processed residue, Although it can select suitably according to the objective, 3 mass% or more is preferable, 5 mass% or more is more preferable, 10 mass % Or more is particularly preferable.
The content of the sapogenin can be measured by, for example, liquid chromatography.

  There is no restriction | limiting in particular as content of the said acid-processed residue in the said uric acid value fall composition, According to the objective, it can select suitably. Further, the uric acid level reducing agent composition may be the acid-treated product itself.

<Other ingredients>
There is no restriction | limiting in particular as said other component, In the range which does not impair the effect of this invention, it can select suitably according to the objective.
There is no restriction | limiting in particular also as content of the said other component in the said uric acid value fall composition, According to the objective, it can select suitably.

<Manufacturing method>
As described above, the residue of the acid-treated product of the genus Tochibanin genus plant is obtained by subjecting the genus Tochibanin genus plant to hydrolysis treatment in the presence of a strong acid aqueous solution and a lower alcohol, followed by hydrofiltration.
In particular, from the viewpoint of efficiently obtaining the acid-treated product residue, it is preferably produced by the following production method.

That is, the acid-treated product residue is obtained by hydrolyzing the arginaceae plant in the presence of a strong acid aqueous solution having a predetermined concentration and a lower alcohol (hydrolysis treatment step), and the resulting hydrolyzed solution is obtained. After neutralization (neutralization step), it is subjected to hydrofiltration (hydrofiltration step), and the residue separated by filtration is dried (drying step).
Hereinafter, the preferable manufacturing method will be described in detail.

<< Hydrolysis treatment process >>
In the hydrolysis treatment step, the Argyceae Tochibanin ginseng plant is hydrolyzed in the presence of a strong acid aqueous solution and a lower alcohol at a predetermined concentration to produce the acid-treated product.

The strong acid aqueous solution is not particularly limited as long as it is an aqueous solution containing a strong acid, and can be appropriately selected according to the purpose. Among these, an aqueous solution containing an inorganic acid such as hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, etc. An aqueous solution containing hydrochloric acid is particularly preferable. The acid concentration in the strong acid aqueous solution is 0.01 mol / L to 4 mol / L, and among these, 0.5 mol / L to 3 mol / L is preferable.
When the concentration of the acid is less than 0.01 mol / L, there is a problem that hydrolysis is insufficient and the acid-treated product is not efficiently generated. When the acid concentration exceeds 4 mol / L, hydrolysis proceeds excessively, There is a problem that it is disadvantageous in terms of cost. On the other hand, when the acid concentration is within the preferable range, it is advantageous in that an acid-treated product can be obtained efficiently by sufficient hydrolysis.

It is preferable that the strong acid aqueous solution is used in a volume of 2 to 20 times the volume of the genus Tochibaninjin.
When the amount of the strong acid aqueous solution used is less than 2 times the volume of the genus Tochibanin ginseng plant, the Uchigaceae Tochibanin ginseng plant may not be sufficiently immersed and the hydrolysis treatment may be insufficient. If the capacity exceeds 20 times, it may be disadvantageous in terms of cost.

<<< Use of lower alcohol >>>
The hydrolysis treatment is performed in the presence of a lower alcohol. By using the lower alcohol, it is possible to improve the affinity between the Argiaceae Tochibanin genus plant and the strong acid aqueous solution, and to proceed the hydrolysis efficiently. Further, the use of the lower alcohol is also advantageous in that the taste and handleability of the resulting acid-treated residue can be improved.
The lower alcohol is not particularly limited and may be appropriately selected depending on the intended purpose. Among these, methanol, ethanol and propanol are preferable, and ethanol is particularly preferable from the viewpoint of safety.
In addition, in this specification, a lower alcohol shows a C1-C4 alcohol compound.

Although there is no restriction | limiting in particular as the usage-amount of the said lower alcohol, It is preferable that it is 1 volume%-80 volume% with respect to the total amount of a hydrolysis liquid, It is more preferable that it is 10 volume%-50 volume%, It is particularly preferably 20% by volume to 40% by volume.
If the amount of the lower alcohol used is less than 1% by volume relative to the total amount of the hydrolyzed solution, an acid-treated product may not be obtained efficiently. If the amount used exceeds 80% by volume, the acid is efficiently obtained. There are cases in which a processed product cannot be obtained and the cost becomes disadvantageous. On the other hand, when the amount of the lower alcohol used is within the particularly preferred range, it is advantageous in that an acid-treated product can be obtained efficiently. The “total amount of hydrolyzed liquid” refers to the total amount of the reaction liquid including the strong acid aqueous solution and the lower alcohol.

Although there is no restriction | limiting in particular as total reaction liquid quantity (hydrolysis liquid total amount) including the said strong acid aqueous solution and the said lower alcohol, It shall be 2 times capacity-20 times capacity with respect to the said Araceae Tochibanin genus plant. Is preferred.
If the total amount of the reaction solution is less than 2 times the volume of the genus Tochibanin genus, the hydrolysis treatment may be insufficient due to insufficient immersion, and if it exceeds 20 times the cost, May be disadvantageous.

Although there is no restriction | limiting in particular as processing temperature in the said hydrolysis process, 60 to 100 degreeC is preferable and 70 to 90 degreeC is more preferable.
If the treatment temperature is less than 60 ° C, hydrolysis may be insufficient and the acid-treated product may not be produced efficiently. If the treatment temperature exceeds 100 ° C, special production equipment is required, which is disadvantageous in terms of cost. There are things to become. On the other hand, when the treatment temperature is within the more preferable range, it is advantageous in that the acid-treated product can be obtained efficiently.

The treatment time in the hydrolysis treatment is not particularly limited, but is preferably 30 minutes to 24 hours, and more preferably 2 hours to 8 hours.
If the treatment time is less than 30 minutes, hydrolysis may be insufficient and an acid-treated product may not be obtained efficiently. If the treatment time exceeds 24 hours, the reaction proceeds excessively or the cost is disadvantageous. There are things. On the other hand, when the treatment time is within the more preferable range, it is advantageous in that the acid-treated product can be obtained efficiently.

<< Neutralization process >>
In the neutralization step, the obtained hydrolyzed solution is neutralized after the hydrolysis treatment.
The neutralization is not particularly limited and can be performed by a known method. For example, the neutralization is performed by appropriately adding a strong base aqueous solution such as sodium hydroxide or potassium hydroxide to the liquid after the hydrolysis treatment. Can do. In addition, it is preferable that the pH after the said neutralization shall be 5-8.

<< Hydrofiltration process >>
In the filtration step, the hydrolyzed liquid after the neutralization step is hydrofiltered and separated into a filtrate and a residue.
The hydrofiltration is not particularly limited and can be performed by a known method. After filtration, washing with water may be repeated until there is no more salt.

<<< Hydrofiltration >>>
Since the lower alcohol is used, water is added to lower the concentration of the lower alcohol in the solution after the hydrolysis treatment for the purpose of promoting the residue in the acid-treated product residue before filtration.
In this case, the lower alcohol concentration in the liquid after the hydrolysis treatment is better as it is lower. Therefore, the more water is added, the lower alcohol concentration in the liquid after the hydrolysis treatment is 50% by volume or less. It is preferable to add to 30% by volume, more preferably 30% by volume or less, and particularly preferably 10% by volume or less.
When the lower alcohol concentration in the liquid after the hydrolysis treatment is subjected to filtration while exceeding 50% by volume, it is disadvantageous in that the obtained acid-treated product is dissolved in the lower alcohol and discharged as a filtrate. . On the other hand, when the concentration of the lower alcohol in the liquid after the hydrolysis treatment is within a particularly preferable range, it is advantageous in that the acid-treated product residue can be obtained more efficiently.

<< Drying process >>
In the drying step, the residue separated by filtration after the hydrofiltration step is dried to obtain the purified acid-treated product residue.
There is no restriction | limiting in particular in the said drying, It can perform by a well-known method, For example, normal methods, such as freeze drying, ventilation drying, heat drying, and reduced pressure drying, can be utilized.

<Ingestion>
There is no restriction | limiting in particular as an ingestion method of the said uric acid value fall composition, ingestion amount, ingestion frequency, ingestion time, and ingestion object, According to the objective, it can select suitably.
There is no restriction | limiting in particular as said ingestion method, Although it can select suitably according to the objective, The method of ingesting orally is preferable at the point which is easy to continue since it can ingest easily.
The intake amount is not particularly limited and may be appropriately selected in consideration of various factors such as the age, weight, constitution, symptom, and presence / absence of administration of a drug containing another component as an active ingredient. However, the daily intake is preferably at least 1 mg, more preferably 10 mg to 1,000 mg, still more preferably 20 mg to 500 mg, and particularly preferably 30 mg to 300 mg.
There is no restriction | limiting in particular as said frequency | count of ingestion, Although it can select suitably according to the objective, Once a day is preferable at the point with the convenience. Moreover, it is preferable to ingest continuously for a long time.
The animal species to be ingested are those that are suitably applied to humans, but as long as their effects are exerted, animals other than humans (eg, mice, rats, hamsters, birds, dogs, Cat, sheep, goat, cow, pig, monkey, etc.). The uric acid level-lowering composition is advantageous in that it has a particularly excellent uric acid level-lowering effect on a human with hyperuricemia whose uric acid level exceeds 7.0 mg / dL when the ingestion target is a human. is there.

<Application>
The uric acid level-lowering composition can be used for various applications such as pharmaceuticals, quasi drugs, general foods, health foods and health drinks, health functional foods, food additives, feeds, feed additives, and the like. As a form at that time, it can be provided as a dry powder, or it can be prepared as a liquid, tablet, powder, granule, dragee, capsule, suspension, emulsion, ampoule, injection, or any other form. It can also be provided.

The uric acid level lowering composition can be used as a therapeutic agent such as a blood uric acid level lowering agent, a hyperuricemia preventing agent, a hyperuricemia improving agent, a gout preventing agent and a gout improving agent by formulation.
There is no restriction | limiting in particular as the method of the said formulation, According to the objective, it can select suitably, For example, it can carry out by a well-known formulation technique, A suitable additive can also be added in a formulation.

  EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated in detail, this invention is not limited to this Example at all.

<Preparation of uric acid level lowering composition>
Example 1
300 g of ginseng powder is added to 0.48 L of hydrochloric acid (35.0 mass% to 37.0 mass%: manufactured by Wako Pure Chemical Industries, Ltd.), 1.52 L of distilled water, and 99.5% ethanol (Wako Pure). 1 L of Yakuhin Kogyo Co., Ltd. was added, and the mixture was stirred and heated at 80 ° C. for 6 hours.
Subsequently, 5M aqueous sodium hydroxide solution was added to the resulting reaction solution to adjust the pH to 7.0, 12.5 L of distilled water was added, the solution was then filtered, and the filtrate and the residue were separated by filtration.
The obtained residue was lyophilized to obtain 52.0 g of a uric acid value-reducing composition of Example 1 consisting of a residue of a processed ginseng acid residue (yield 17.3%).

(Comparative Example 1)
The same ginseng powder as the ginseng powder used in Example 1 was used as the uric acid value-reducing composition of Comparative Example 1.

<Test of uric acid level lowering effect (I)>
-Test method-
The blood uric acid level of 20 adults was measured and divided into two groups so that the uric acid level would be average. One capsule encapsulating 1.0 g of the uric acid level lowering composition (Tanachi ginseng powder) of Comparative Example 1 On the other hand, a capsule encapsulating 173 mg (corresponding to 1.0 g of ginseng powder) of the uric acid level-reducing composition of Example 1 was ingested once in the morning on an empty stomach, Continued for 2 weeks.

-Test results-
As understood from Table 1 below, in the Group 7 ginseng powder ingestion group using the uric acid level lowering composition of Comparative Example 1, before ingestion and after ingestion for 2 weeks, after ingestion for 2 weeks, The uric acid level only decreased by 0.2 mg / dL. On the other hand, in the ingestion group of the processed ginseng acid residue using the uric acid level-lowering composition of Example 1, before the ingestion and after the ingestion for 2 weeks, the one after the ingestion for 2 weeks was 0. It decreased by 66 mg / dL, and a significant decrease in uric acid level was observed.
A statistical analysis was performed on the uric acid level decrease in the group of ginseng powder after 2 weeks intake and the uric acid level decrease in the group of ginseng treated residues using the Student t test. It was 0.02, and a statistically significant difference was observed in the decrease in uric acid level in the group of the seven ginseng treated residues.

<Test for prevention and improvement of hyperuricemia>
-Test method-
In the evaluation of the uric acid level lowering effect, for the subjects ingesting the residue of processed ginseng acid using the uric acid level lowering composition of Example 1, further grouping as shown in the following (1), (2) The uric acid level was measured for each group by the method shown below.
(1) 4-week intake group (Subjects 11-15)
In this group, following the above-described test for uric acid level lowering effect (continuous intake for 2 weeks), the uric acid level lowering composition in Example 1 was continuously ingested for a further 4 weeks.
(2) 2 weeks after interruption (subjects 16-20)
In this group, in the test for the effect of lowering uric acid level (continuous intake for 2 weeks), the intake was interrupted and then continued for 2 weeks so that the uric acid level-lowering composition in Example 1 was not taken.

-Test results-
The uric acid level after completion of the test was measured for each subject in the (1) 4-week intake group and the (2) 2-week post-interruption group. The results are shown in Table 2 below.
As can be seen from Table 2 below, the (1) 4-week intake group showed a significantly lower uric acid value than the (2) 2-week post-interruption group.
That is, in the group of 2 weeks after the interruption (2), a low uric acid level state is not maintained when comparing 2 weeks after the start of intake and at the end of the test (2 weeks after stopping the intake) ( (Increased uric acid level of 0.6 mg / dL on average), (1) In the 4-week intake group, compared to 2 weeks after the start of intake and at the end of the test (4 weeks after the start of intake), low It was confirmed that the uric acid level state was maintained (the uric acid level decreased by 0.18 mg / dL on average).
The difference in uric acid levels compared between 2 weeks after the start of intake in the 4-week intake group and at the end of the study (4 weeks after start of intake), and 2 weeks after the start of intake in the group after 2 weeks and at the end of the test (intake) The statistical analysis of the difference in uric acid value compared to 2 weeks after the interruption was performed using Student's t-test, the risk rate was P = 0.05, which was statistically significant in the uric acid value lowering effect The difference was recognized.
As described above, if the uric acid value-lowering composition in Example 1 is continuously ingested, an increase in the uric acid value can be suppressed, and if the uric acid value-lowering composition is interrupted, the uric acid value increases. It is speculated that the uric acid level-lowering composition of the present invention can contribute to prevention and improvement of hyperuricemia.

<Test of uric acid level lowering effect (II)>
Adults (blood hyperuricemia group) who have a blood uric acid level that is more than 7.0 mg / dL, an index for determining hyperuricemia, and adults whose blood uric acid level is 7.0 mg / dL or less A test of the effect of lowering uric acid levels was carried out using (normal uric acid level group) as subjects.

(Example 2: Preparation of high dose)
Using the rice ginseng acid processed product residue obtained in Example 1, 1.0 g of crystalline cellulose containing 180 mg of the ginseng acid processed product was encapsulated in a capsule, and the uric acid value-reducing composition in Example 2 (hereinafter referred to as the uric acid value-reduced composition) , Sometimes referred to as “high dose”).

(Example 3: Preparation of low dose)
Using the rice ginseng acid processed product residue obtained in Example 1, 1.0 g of crystalline cellulose containing 45 mg of the ginseng acid processed product was encapsulated in a capsule, and the uric acid value-reducing composition in Example 3 (hereinafter referred to as “the uric acid value reduced composition”) , Sometimes referred to as “low dose”).

(Comparative Example 2: Preparation of placebo)
The decrease in uric acid level in Comparative Example 2 was performed in the same manner as in Example 2 and Example 3, except that 1.0 g of crystalline cellulose not containing the residue of the processed ginseng acid product obtained in Example 1 was encapsulated. A composition (hereinafter sometimes referred to as “placebo”) was prepared.

-Test method-
Twelve adults (blood hyperuremia group: subjects 59 to 70) with blood uric acid levels that are more than 7.0 mg / dL, which are indicators of hyperuricemia, and blood uric acid levels of 7 0.0 38 mg / dL or less adults (normal uric acid level group: subjects 21 to 58) were subjects, and the blood uric acid level was measured for each of the hyperuricemia group and the normal uric acid level group, The uric acid level is divided into three groups so that the uric acid level becomes average, a placebo group (subjects 21-33, 59-63), a low dose group (subjects 46-58, 68-70), a high dose group (subjects 34-45, Three groups of 64 to 67) were set. In the placebo group, the uric acid lowering composition of Comparative Example 2 was ingested, in the low dose group, the uric acid lowering composition of Example 3, and in the high dose group, the uric acid lowering composition of Example 2 was ingested once in the morning on an empty stomach. This was continued for 12 weeks.

-Test results-
The results of the normal uric acid value group are shown in Table 3 below, and the results of the hyperuricemia group are shown in Table 4 below.
As can be seen from Table 3, in the normal uric acid level group with a blood uric acid level of 7.0 mg / dL or less, there was no significant change in the blood uric acid level before and after 12 weeks of ingestion. It was.
On the other hand, as can be seen from Table 4, in the hyperuricemia group in which the blood uric acid level exceeded 7.0 mg / dL, the placebo group was 12 weeks after ingestion before and 12 weeks after ingestion. The blood uric acid level increased by 0.36 mg / dL. In contrast, in the low-dose group ingesting the uric acid level-lowering composition of Example 3, the blood uric acid level was 0.47 mg / dL before ingestion and 12 weeks after ingestion, 12 weeks after ingestion. When the measurement results were analyzed using the Student t test, the risk factor P was 0.10, and a moderate uric acid value lowering effect was observed. Furthermore, in the high-dose group ingesting the uric acid level-lowering composition of Example 2, the blood uric acid level decreased by 0.6 mg / dL before ingestion and after 12 weeks of ingestion after 12 weeks of ingestion. In addition, when the measurement results were analyzed using the student t test, the risk factor P = 0.04, and a statistically significant difference was observed in the uric acid level lowering effect.
In all groups, no adverse effects were observed in the subjects during the intake period of 12 weeks, and the subjects did not feel any resistance during intake. From these results, it was found that this test composition can be safely and continuously ingested, and can effectively reduce the uric acid level particularly for those who have high blood uric acid levels.

The uric acid level-lowering composition of the present invention lowers the uric acid level in the blood, can be safely and comfortably taken for a long time without side effects, and further contributes to the prevention and improvement of hyperuricemia. It can be suitably used as a uric acid level lowering agent, a hyperuricemia preventing agent, a hyperuricemia improving agent, a gout preventing agent, and a gout improving agent.

Claims (3)

  A composition for reducing uric acid level, which comprises, as an active ingredient, an acid-treated product residue obtained by hydrolyzing a Urugiaceae plant belonging to the genus Tochibaninjin in the presence of a strong acid aqueous solution and a lower alcohol, followed by hydrofiltration.   The uric acid level-decreasing composition according to claim 1, wherein the Arionaceae Tochibaninjin plant is a ginseng.   The uric acid level lowering composition according to any one of claims 1 to 2, which is used for a blood uric acid level lowering agent, a hyperuricemia preventing agent, a hyperuricemia improving agent, a gout preventing agent and a gout improving agent.